Transplant Diagnostics Market Outlook 2031
The global transplant diagnostics market size was USD 4.40 Billion In 2022 and is projected to reach USD 8.37 Billion by 2031 expand a significant CAGR 7.4% during the forecast period, 2023 – 2031. The growth of the market is attributed to the rising organ transplants. Demand for organ transplants are always higher than supply of organs.
Still, research and analysis are widely conducted to reduce the gaps between demand and supply of organs that are likely to give benefits to several patients who need to undergo transplant. Initiatives taken by European Commission for organ harvesting present a major step to help in providing the needs of patients for making availability of donated organs. Organ donation rate has increased in the region due to accessibility of the European donor card and rising awareness between individuals.
Moreover, the US has experienced a significant growth of organ donation over the decades because of growing awareness among a large number of population in the country. Additionally, growing number of chronic disease patients mostly have higher change of organ failure, which prove to be a key factor that pushes the demand for the process of organ transplantation.
Furthermore, personalized demand and acceptance of stem cell therapy are accelerating the rapid growth in demand for pre-procedure diagnostics. While undergoing the organ transplant process, there is complexity and risk related to it. Hence, there is constant requirement for improvement and use of sophisticated diagnostic tools.
Traditional diagnostic methods such as serological techniques employed in Human Leukocyte Antigen (HLA) typing are swiftly replaced by Next Generation Sequencing (NGS) technology because of demand for more efficient diagnostic tools including enhanced accuracy.
Transplant Diagnostics Market Trends, Drivers, Restraints, and Opportunities
- Rising incidence of organ failure due to tragic accidents and rising cases of chronic illness is projected to propel the market growth in the coming years.
- Trend of gradual transition to organ donation from various individuals and governments’ policies to encourage such donation are key drivers for the market.
- Growing development of innovative diagnostics kits and equipment to ensure accurate and effective transplant testing is another major driving factor that can boost the market.
- High cost of using PCR and NGS devices diagnostics and certain complicacies in handling the organs transplant are projected to hamper the market growth.
- Poor reimbursement policies and strict regulatory protocols from regulatory bodies across the globe are key factors that can restrict the market growth.
- Technological advancement and ongoing R&D activities to expand diagnostics products are offering several opportunities for the market expansion during the forecast period.
Scope of The Transplant Diagnostics Market Report
The report on the global transplant diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Transplant Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Technology (Molecular Assays and Non-molecular Assays) and Products (Reagents & Consumables, Instruments, and Software & Services)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Thermo Fisher Scientific, Inc.; Illumina, Inc.; F. Hoffmann La-Roche AG.; Abbott Laboratories, Inc.; Qiagen N.V.; Immucor Transplant Diagnostics, Inc.; Bio-rad Laboratories, Inc.; Affymetrix, Inc.; and Omixon Ltd.
Transplant Diagnostics Market Segment Insights
Molecular assays segment is projected to account for a key market share
Based on technology, the transplant diagnostics market is bifurcated into molecular assays and non-molecular assays. The molecular assays segment is expected to account for a key share of the market during the forecast period owing to rising preference for molecular assays over non-molecular assays from physicians. Moreover, there is a significant shift from serological assays to HLA typing due to its advantages such as low risk, accuracy, and efficacy.
Recently, the PCR-based assay segment is increasingly adopted due to its usage in multiple applications. To ensure procedures are safe and effective, the pre-transplantation analysis techniques are used, which are widely preferred by majority of physicians due to its quick result.
Software & Services segment is expected to grow at a rapid pace
On the basis of products, the market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment is expected to constitute a key share of the market in the coming years owing to increasing their repeat purchase. On the other hand, the services & software segment is anticipated to expand at a rapid pace during the forecast period due to increase in introduction of sophisticated instruments for diagnostics.
Growing demand for training sessions for technical staff related to use and handling of instruments is another key factor boosting the segment growth. Additionally, improved services provided by market players and frequent software updates are major factors for the growth market.
North America is expected to dominate the market
In terms of regions, the transplant diagnostics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to advanced technique, high expenditure on healthcare, skilled professional’s availability, and advanced diagnostic tools.
The US is currently holding a major market share in the region due to factors such as skilled professional’s availability and well developed healthcare infrastructure. Furthermore, rising demand for soft tissue transplants, adoption of personalized medicines, and growing stem cell therapies are boosting the market growth in the region. On the other hand, strict organ donors’ reimbursement policies from regulation bodies and their legislation such as the Organ Transplantation Act present key challenges, which can hamper the regional market growth.
The global transplant diagnostics market has been segmented on the basis of
- Reagents & Consumables
- Software & Services
- Molecular Assay
- PCR-based Molecular Assay
- Sequencing-based Molecular Assay
- Non-molecular Assay
- Serological Assay
- Mixed Lymphocyte Culture Assay
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- F. Hoffmann La-Roche AG.
- Abbott Laboratories, Inc.
- Qiagen N.V.
- Immucor Transplant Diagnostics, Inc.
- Bio-rad Laboratories, Inc.
- Affymetrix, Inc.
- Omixon Ltd.
Key players competing in the transplant diagnostics market are Thermo Fisher Scientific, Inc., Illumina, Inc., F. Hoffmann La-Roche AG., Abbott Laboratories, Inc., Qiagen N.V., Immucor Transplant Diagnostics, Inc., Bio-rad Laboratories, Inc., Affymetrix, Inc., and Omixon Ltd.
Some of these players are implementing several market strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, on December 2020, one of the global leaders in the market, Thermo Fisher Scientific had announced that it would expand its presence in Europe and North America for therapies, sterile drug product development, and vaccines and critical medicine’s commercial manufacturing.